-

BostonGene and Kyoto University Partner to Accelerate Precision Drug Development

AI-Powered Multiomics Platform to Drive Predictive Biomarker Identification and Personalized Therapies

WALTHAM, Mass. & KYOTO, Japan--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for cancer and the immune system, and Kyoto University, a research institution known for its groundbreaking advancements in medicine and science announced today a research collaboration to develop advanced biological signatures to enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC).

"Through this collaboration, we will apply cutting-edge AI-powered analytics to clinical data, enabling us to identify biomarkers that can directly inform treatment decisions and improve patient outcomes."

Share

This research will leverage BostonGene’s AI-powered, multi-scale, omnimodal platform to analyze tumor molecular profiles and assess their correlation with response to a novel immune checkpoint inhibitor (ICI) and chemoradiotherapy (CRT) combination therapy. The study builds on the NOBEL trial, an investigator-initiated clinical study led by Dr. Manabu Muto of Kyoto University, by integrating genomic and transcriptomic profiling from ESCC patients to identify immune-related biomarkers that drive drug development, optimize clinical trial design and enable more accurate patient stratification.

As part of the collaboration, Kyoto University will provide clinical samples and patient data and BostonGene will apply its AI-powered molecular analytics to uncover key biological pathways and associated biomarkers influencing treatment response.

"This collaboration will generate actionable insights into the tumor microenvironment and immune landscape of esophageal cancer," said Yukimasa Shiotsu, PhD, President of BostonGene Japan. "Combining Kyoto University’s clinical expertise and BostonGene’s AI-powered analytics, we will refine and advance precision treatment strategies for ESCC patients."

"Understanding the molecular and immune characteristics of ESCC is essential for developing more effective treatment strategies," said Dr. Manabu Muto, Professor at Kyoto University and Principal Investigator of the NOBEL trial. "Through this collaboration, we will apply cutting-edge AI-powered analytics to clinical data, enabling us to identify biomarkers that can directly inform treatment decisions and improve patient outcomes."

About NOBEL trial

NOBEL trial is a Phase II study evaluating the efficacy and safety of a combination treatment of chemoradiotherapy and an immune checkpoint inhibitor for advanced esophageal cancer.

The NOBEL trial is being conducted as an investigator-initiated trial with financial support from Ono Pharmaceutical Co., Ltd.

About BostonGene Corporation

BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.

About BostonGene Japan

BostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene’s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient.

About Kyoto University

Kyoto University states its mission to sustain and develop its historical commitment to academic freedom and to pursue harmonious coexistence within the human and ecological community on this planet. For more information, visit https://www.kyoto-u.ac.jp/en/about/profile/ideals

Contacts

Media contact
BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@bostongene.com

BostonGene LogoBostonGene Logo

BostonGene


Release Versions

Contacts

Media contact
BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@bostongene.com

Social Media Profiles
More News From BostonGene

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom